• AMERY, A., DePLAEN, J., LIJNEN, P., McAINSH, J. & REYBROUK, T. (1977). Relationship between blood level of atenolol & pharmacologic effect Clin. Pharmac. Ther., 21, 691699.
  • AMERY, A., BILLIET, L., JOOSSENS, J.V., MEEKERS, J., REYBROUK, T. & VAN MIEGHEM, W. (1973). Preliminary report on the hemodynamic response of hypertensive patients treated with a β-blocker (ICI 66082). Acta Clinica Belgica, 29, 358363.
  • BARRETT, A.M., CARTER, J., FITZGERALD, J.D., HILL, R. & LE COUNT, D. (1973). A new type of cardioselective adrenoceptive blocking drug. Br. J. Pharmac., 48, 340P.
  • BROWN, H.C., CARRUTHERS, S.G., JOHNSTON, G.D., KELLY, J.G., McAINSH, J., McDEVITT, D.G. & SHANKS, R.G. (1976). Clinical pharmacologic observations on atenolol a β-adrenoceptor blocker. Clin. Pharmac. Ther. 20, 524534.
  • CONWAY, F.J., FITZGERALD, J.D., McAINSH, J., ROWLANDS, D.J. & SIMPSON, W.T. (1976), Human pharmacokinetic and pharmacodynamic studies on atenolol (ICI 66082), a new cardioselective β-adrenoceptor blocking drug. Br. J. clin. Pharmac. 3, 267272.
  • GRAHAM, B.R., LITTLEJOHNS, D.W., PRICHARD, N.B.C., SCALES, B. & SOUTHORN, P. (1973). Preliminary observations on the human pharmacology of ICI 66082 in volunteers. Br. J. Pharmac., 49, 154P.
  • HAINSWORTH, R., KARIM, F. & STOKER, J.B. (1974). Blockade of peripheral vascular responses to isoprenaline by three β-adrenoceptor antagonists in the anesthetized dog. Br. J. Pharmac., 51, 161168.
  • HANSSON, L., ABERG, H., JAMESON, S., KARLBERG, B. & MALMERONA, R. (1973). Initial clinical experience with ICI 66082, a new β-adrenergic blocking agent, in hypertension. Acta Med. Scand., 194, 549550.
  • HARRY, J.D., KNAPP, M.F. & LINDEN, R.J. (1973). The action of ICI 66082 on the heart. Br. J. Pharmac., 48, 340P341P.
  • HARRY, J.D., KNAPP, M.F. & LINDEN, R.J. (1974). The actions of a new β-adrenoceptor blocking drug, ICI 66082, on the rabbit papillary muscle and on the dog heart. Br. J. Pharmac., 51, 169177.
  • MALBICA, J.O. & MONSON, K.R. (1975). New and expedient determination of atenolol in biological samples. J. pharm. Sci., 64, 19921994.
  • MATIN, S.B., WAN, S.H. & KARAM, J. (1974). Pharmacokinetics of tolbutamide in man: prediction by tolbutamide concentration in saliva. Clin. Pharmac. Ther., 16, 10521058.
  • McAINSH, J. (1977). Clinical pharmacokinetics of atenolol. Postgrad. med. J., 53, (Suppl. 3) 7478.
  • METZLER, C.M. (1969). NONLIN, a computer program for parameter estimation in nonlinear situations. Technical report 7292/69/7292/005. Kalamazoo, Michigan: The Upjohn Company.
  • SASSARD, J., POZER, N., McAINSH, J., LEGHEARD, J. & ZECH, P. (1977). Pharmacokinetics of atenolol in patients with renal impairment. Eur. J. clin. Pharmac., 12, 175180.
  • SHANKS, R.G., CARRUTHERS, S.G. KELLY, J.G. & McDEVITT, D.G. (1977). Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad. med. J., 53, (Suppl. 3) 7073.
  • WAN, S.H., MARONDE, R.F. & MATIN, S.B. (1978). GLC determination of atenolol and some β-blocking agents from biological fluids. J. pharm. Sci., 67, 13401342.
  • WAN, S.H., MATIN, S.B. & AZARNOFF, D.L. (1978). Pharmacokinetics, salivary excretion of amphetamine isomers, and effect of urine pH. Clin. Pharmac. Ther., 23, 585590.